StocksDiva Bio Bin

[PoemStone]

BIO. after/hours. Bio-Rad Reports First-Quarter 2012 Financial Results
http://finance.yahoo.com/news/bio-rad-reports-first-quarter-201500539.html

HERCULES, CA--(Marketwire -05/01/12)- Bio-Rad Laboratories, Inc. (BIO - News) (BIO-B - News), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2012.

First-quarter reported revenues were $486.3 million, up 0.2% compared to $485.1 million reported for the first quarter of 2011. On a currency-neutral basis, quarterly revenues increased 1.4% compared to the same period last year. First-quarter gross margin was 57.3% compared to 57.2% during the same quarter last year. Net income attributable to Bio-Rad for the first quarter of 2012 was $31.0 million, or $1.09 per share on a fully diluted basis compared to $1.16 per share during the same period last year. These results include $7.7 million in operating losses (including approximately $2.5 million of amortization expense) resulting from Bio-Rad's acquisition of QuantaLife, Inc., in October 2011. First-quarter results also reflect recognition of an indirect tax in Brazil for the periods of 2007 through 2011 totaling $6.1 million.

"While we are off to a little bit of a slow start for the year, our outlook remains positive," said Norman Schwartz, Bio-Rad President and Chief Executive Officer.

Life Science
The Life Science segment net sales for the first quarter were $154.8 million, up 0.2% compared to the first quarter of 2011. On a currency-neutral basis, Life Science segment sales increased 0.7% compared to the same period last year. Results for the Life Science segment benefitted from sales of electrophoresis, imaging, and western blot products as well as application reagents. Recently introduced products, including the V3 Western Workflow™ system and the QX100™ Droplet Digital™ PCR system continued to gain rapid customer acceptance during the first quarter of 2012.

Clinical Diagnostics
Net sales for the Clinical Diagnostics segment in the first quarter of 2012 were essentially flat at $327.2 million compared to the first quarter for 2011. On a currency-neutral basis, net sales were up 1.6% compared to the same period last year. The company's year-over-year results were impacted by a one-time sale of blood typing products to Japan during the first quarter of 2011. Without this one-time sale, growth for the Clinical Diagnostics segment in the first quarter of 2012 would have shown an increase of approximately 4% on a currency neutral basis.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) May 1, 2012. Interested parties may access the call by dialing 800-299-6183 (in the U.S.) or 617-801-9713 (international), access number 23066392.

A live webcast of the conference call may be accessed in the "Investor Relations" section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), access number 73110502, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site for on-demand replay for up to a year and may be accessed in the "Investor Relations" section of www.bio-rad.com.

About Bio-Rad
Bio-Rad Laboratories, Inc. (BIO - News) (BIO-B - News) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,000 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.